Analyst Jonathan Chang from Leerink Partners reiterated a Hold rating on Adaptimmune Therapeutics (ADAP – Research Report) and keeping the price target at $2.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Jonathan Chang’s rating is based on a combination of factors, including Adaptimmune Therapeutics’ recent financial performance and strategic developments. The company reported first-quarter 2025 revenues from Tecelra that were slightly below market expectations, although there was a noticeable increase from the previous quarter. Additionally, the number of authorized treatment centers has grown, indicating potential for future revenue growth.
Despite these positive signs, the company’s financial liquidity remains a concern, with ongoing exploration of strategic options to extend its operational runway. Furthermore, while there are promising developments in the pipeline, such as the anticipated BLA submission for lete-cel and potential commercial launches, these are expected to materialize in the longer term. As such, the Hold rating reflects a cautious stance, balancing current performance with future potential.
According to TipRanks, Chang is an analyst with an average return of -13.0% and a 28.10% success rate. Chang covers the Healthcare sector, focusing on stocks such as Zai Lab, Nanobiotix, and Xencor.
In another report released yesterday, Wells Fargo also maintained a Hold rating on the stock with a $1.00 price target.